Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
Benjamin K WatkinsMuna QayedCourtney McCrackenBrandi BratrudeKayla BetzYvonne SuessmuthAlison YuShauna SinclairScott N FurlanSteven BosingerVictor TkachevJames RhodesAudrey Grizzle TumlinAlexandria NarayanKayla CribbinScott GillespieTed A GooleyMarcelo C PasquiniKyle HebertUrvi KapoorAndre RogatkoMourad TighiouartSungjin KimCatherine BreseeSung Won ChoiJeffrey H DavisChristine DuncanRoger H GillerMichael S GrimleyAndrew C HarrisDavid JacobsohnNahal LalefarMaxim NorkinNosha FarhadfarMichael A PulsipherShalini ShenoyAleksandra PetrovicKirk R SchultzGregory A YanikEdmund K WallerJohn E LevineJames L M FerraraBruce R BlazarAmelia A LangstonJohn T HoranLeslie S KeanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Adding abatacept to URD HCT was safe, reduced AGVHD, and improved SGFS. These results suggest that abatacept may substantially improve AGVHD-related transplant outcomes, with a particularly beneficial impact on HLA-mismatched HCT.